Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Profound Medical Corp T.PRN

Alternate Symbol(s):  PROF

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low -, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.


TSX:PRN - Post by User

Bullboard Posts
Comment by ebrie014on Jun 30, 2017 1:29pm
126 Views
Post# 26424845

RE:Interesting - see where this goes ...

RE:Interesting - see where this goes ...I second that; very interesting.

I great strategic move to become a specialist in MRI guided technology and not just prostate cancer. Its also nice to see that they are doing it above the current share price gpood indication they know its undervalued at current price.

Expanded market reach (MR-HIFU, as a technology, has also been shown to have clinical application in other medical conditions, including non-invasive ablation of abdominal cancers, hyperthermia for cancer therapy and palliative pain treatment of bone metastases.), expanded sales agreement with philips to sell both technologies, good long term positioning for the company, technology already approved in EU should help increase revenues/get to cash flow positive at a faster rate.

Well done - I've become slightly more positive about this story with this development. (I think this positions them even better to be taken out by a big player as they are now not just a "one trick pony" but have broader MRI applications.
Bullboard Posts